Denali Advisors LLC Has $689,000 Stock Position in AstraZeneca PLC $AZN

Denali Advisors LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 35.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,975 shares of the company’s stock after selling 5,002 shares during the period. Denali Advisors LLC’s holdings in AstraZeneca were worth $689,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. NewSquare Capital LLC grew its stake in AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after acquiring an additional 218 shares during the period. Rakuten Investment Management Inc. bought a new position in AstraZeneca in the third quarter valued at $31,000. FSA Wealth Management LLC grew its holdings in shares of AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after acquiring an additional 376 shares in the last quarter. VSM Wealth Advisory LLC acquired a new position in shares of AstraZeneca during the 2nd quarter worth approximately $33,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its holdings in AstraZeneca by 144.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after buying an additional 275 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Citigroup began coverage on AstraZeneca in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Jefferies Financial Group started coverage on shares of AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating on the stock. Wall Street Zen cut AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. TD Cowen reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, December 9th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, January 21st. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus target price of $95.75.

AstraZeneca Stock Up 0.5%

Shares of AZN opened at $205.47 on Tuesday. The stock’s 50-day moving average price is $115.01 and its two-hundred day moving average price is $93.99. AstraZeneca PLC has a 12 month low of $122.48 and a 12 month high of $206.71. The company has a market capitalization of $318.66 billion, a PE ratio of 68.26, a PEG ratio of 1.59 and a beta of 0.34. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54.

AstraZeneca Announces Dividend

The business also recently announced a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be paid a dividend of $1.595 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a yield of 165.0%. AstraZeneca’s dividend payout ratio is currently 74.83%.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.